AFP and hepatocellular carcinoma: In a prospective multicenter cohort study including 3012 patients with chronic HCV infection, Nakano et al. found that a higher AFP level before DAA therapy (at a cut-off value of AFP ≥ 5.4 ng/ml), indicated a higher risk of HCC recurrence after curative treatment (p = 0.0047) [49].